ACTU Study for People Experiencing Protease Inhibitor Failure
March 31, 2000
The University of Washington AIDS Clinical Trials Unit has a new study for people who are experiencing protease inhibitor failure of specific drugs within that class. Eligible people will include:
People selected for the study will be given indinavir and ritonavir in two dose combinations (given twice daily) and must be on two nucleoside analogs prescribed by their primary care provider. (The study supplies the protease inhibitors, the participant supplies their own nucleoside analogs.)
If you are interested in this study, and want to find out more about eligibility, you may contact Margot Perrin, Karen Novak, or Carol Glenn at the ACTU. Their phone number is 206-731-3184. Be sure to reference study number 5055 when you call.
This article was provided by Seattle Treatment Education Project. It is a part of the publication STEP Ezine.